Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Michiko Itoi-Babaya is active.

Publication


Featured researches published by Michiko Itoi-Babaya.


Diabetes | 2007

Prevention and Treatment of Obesity, Insulin Resistance, and Diabetes by Bile Acid–Binding Resin

Misato Kobayashi; Hiroshi Ikegami; Tomomi Fujisawa; Koji Nojima; Yumiko Kawabata; Shinsuke Noso; Naru Babaya; Michiko Itoi-Babaya; Kaori Yamaji; Yoshihisa Hiromine; Masao Shibata; Toshio Ogihara

Bile acid–binding resins, such as cholestyramine and colestimide, have been clinically used as cholesterol-lowering agents. These agents bind bile acids in the intestine and reduce enterohepatic circulation of bile acids, leading to accelerated conversion of cholesterol to bile acids. A significant improvement in glycemic control was reported in patients with type 2 diabetes whose hyperlipidemia was treated with bile acid–binding resins. To confirm the effect of such drugs on glucose metabolism and to investigate the underlying mechanisms, an animal model of type 2 diabetes was given a high-fat diet with and without colestimide. Diet-induced obesity and fatty liver were markedly ameliorated by colestimide without decreasing the food intake. Hyperglycemia, insulin resistance, and insulin response to glucose, as well as dyslipidemia, were markedly and significantly ameliorated by the treatment. Gene expression of the liver indicated reduced expression of small heterodimer partner, a pleiotropic regulator of diverse metabolic pathways, as well as genes for both fatty acid synthesis and gluconeogenesis, by treatment with colestimide. This study provides a molecular basis for a link between bile acids and glucose metabolism and suggests the bile acid metabolism pathway as a novel therapeutic target for the treatment of obesity, insulin resistance, and type 2 diabetes.


Diabetologia | 2004

Allelic variation in class I K gene as candidate for a second component of MHC-linked susceptibility to Type 1 diabetes in non-obese diabetic mice

Kaori Inoue; Hiromasa Ikegami; Tomomi Fujisawa; Shinsuke Noso; Koji Nojima; Naru Babaya; Michiko Itoi-Babaya; Susumu Makino; Toshio Ogihara

Aims/hypothesisRecent studies have revealed that MHC-linked susceptibility to Type 1 diabetes is determined by multiple components. In the non-obese diabetic (NOD) mouse, a second component (Idd16) has been mapped to a region adjacent to, but distinct from Idd1 in the class II region. In this study, we investigated the class I K gene as a candidate gene for Idd16.MethodsWe determined the genomic sequences of the class I K gene as well as the reactivity of K molecules with monoclonal antibodies in the NOD mouse, the Cataract Shionogi (CTS) mouse, and the NOD.CTS-H-2 congenic strain, which possesses a resistance allele to Type 1 diabetes at the Idd16 on the NOD genetic background genes.ResultsWhile the K sequence of the NOD mouse was identical to that of Kd type, ten nucleotide substitutions were identified in the CTS mouse compared with the NOD mouse. Of these, three were in exon 4, giving two amino acid substitutions, which were identical to those seen in KK type. These characteristics were retained in the NOD.CTS-H-2 congenic strain, which had a lower incidence and delayed onset of Type 1 diabetes owing to a resistance allele at Idd16. Lymphocytes from NOD.CTS-H2 congenic mice reacted with anti-Kd and anti-Kk monoclonal antibodies, reflecting the unique sequence of the K gene. The nucleotide sequence of the K gene in the non-obese non-diabetic (NON) mouse was also unique, consisting of a combination of Kk- and Kb-like sequences.Conclusions/interpretationThese data suggest that H2-K is unique in CTS and NON mice, and that allelic variation of the class I K gene may be responsible for Idd16.


Diabetologia | 2007

Fatty liver and obesity : phenotypically correlated but genetically distinct traits in a mouse model of type 2 diabetes

Michiko Itoi-Babaya; Hiroshi Ikegami; Tomomi Fujisawa; Hironori Ueda; Koji Nojima; Naru Babaya; Misato Kobayashi; Shinsuke Noso; Yoshihiko Kawaguchi; Kaori Yamaji; Masao Shibata; Toshio Ogihara

Aims/hypothesisObesity and fatty liver are commonly associated with type 2 diabetes, but the genetic and functional bases linking fatty liver with obesity and diabetes are largely unknown. Our aim was to investigate the association of fatty liver with obesity and other diabetes-related phenotypes and to define the genetic control of obesity and fatty liver.Materials and methodsWe established 306 F2 mice by crossing Nagoya–Shibata–Yasuda (NSY) mice, an animal model of type 2 diabetes, with control C3H mice, and analysed their phenotypes. Whole-genome screening of F2 mice was performed to identify the loci responsible for fatty liver and obesity.ResultsA strong association of fatty liver with obesity, hyperinsulinaemia and hyperglycaemia was observed in F2 mice. Using whole-genome screening in 306 F2 mice, we mapped a new locus for fatty liver (Fl1n) on chromosome 6 (maximum logarithm of odds score [MLS] 10.0) and one for body weight (Bw1n) on chromosome 7 (MLS 5.1). Fl1n was linked to epididymal fat weight as well as fatty liver, but its effects were opposite in the two tissues in that the NSY allele increased liver fat but decreased epididymal fat, suggesting a role of Fl1n in partitioning of fat mass. The sequence of peroxisome proliferator-activated receptor γ (Pparg), a candidate for Fl1n, showed allelic variation between NSY and C3H mice.Conclusions/interpretationThese data suggest that fatty liver and obesity are phenotypically related but genetically independent. Loci homologous to Fl1n and Bw1n are good candidate genes for susceptibility to fatty liver and obesity in humans.


Diabetologia | 2010

Direct evidence for susceptibility genes for type 2 diabetes on mouse chromosomes 11 and 14

Naru Babaya; Tomomi Fujisawa; Koji Nojima; Michiko Itoi-Babaya; Kaori Yamaji; Kazunori Yamada; Misato Kobayashi; Hironori Ueda; Yoshihisa Hiromine; Shinsuke Noso; Hiroshi Ikegami

Aims/hypothesisDiabetogenic loci for type 2 diabetes have been mapped to mouse chromosome (Chr) 11 and 14 in the Nagoya–Shibata–Yasuda (NSY) mouse, an animal model of type 2 diabetes. We aimed to obtain direct evidence of these genes on each chromosome and to clarify their function and interaction in conferring susceptibility to type 2 diabetes.MethodsWe established three consomic strains homozygous for diabetogenic NSY-Chr11, NSY-Chr14 or both on the control C3H background (C3H-11NSY, C3H-14NSY and C3H-11NSY14NSY, respectively), and monitored diabetes-related phenotypes longitudinally. The glucokinase gene was sequenced as a positional candidate gene on Chr11.ResultsC3H-11NSY mice showed hyperglycaemia associated with impaired insulin secretion and age-dependent insulin resistance without obesity. C3H-14NSY mice exhibited hyperglycaemia mainly due to insulin resistance, with a slight increase in percentage body fat. C3H-11NSY14NSY double consomic mice showed marked hyperglycaemia and obesity, which was not observed in single consomic strains. Sequences of the glucokinase gene were allelically variant between NSY and C3H mice.Conclusions/interpretationThese data provide direct evidence that Chr11 and Chr14 harbour major susceptibility genes for type 2 diabetes. These two chromosomes interact to cause more severe hyperglycaemia and obesity, which was not observed with the presence of either single chromosome, indicating different modes of gene–gene interaction depending on the phenotype. Marked changes in the phenotypes retained in the consomic strains will facilitate fine mapping and the identification of the responsible genes and their interaction with each other, other genes and environmental factors.


Annals of the New York Academy of Sciences | 2006

MHC-linked susceptibility to type 1 diabetes in the NOD mouse: further localization of Idd16 by subcongenic analysis.

Tomomi Fujisawa; Hiroshi Ikegami; Shinsuke Noso; Kaori Yamaji; Koji Nojima; Naru Babaya; Michiko Itoi-Babaya; Yoshihisa Hiromine; Misato Kobayashi; Susumu Makino; Toshio Ogihara

Abstract:  Although major histocompatibility complex (MHC)‐linked susceptibility is the strongest component, recent studies demonstrated that MHC‐linked susceptibility to type 1 diabetes consists of multiple components both in humans and non‐obese diabetic (NOD) mouse. In the NOD mouse, Idd16 has been mapped to the region adjacent to, but distinct from Idd1 in the MHC class II region. Establishment of subcongenic NOD.CTS‐H2 lines that possess the same MHC class II as the NOD mouse but non‐NOD‐derived chromosomal region in its adjacent regions, would facilitate further narrowing down of the localization of Idd16.


Geriatrics & Gerontology International | 2003

Less frequent body weight gain in elderly type 2 diabetic patients treated with glimepiride

Kaori Inoue; Hiroshi Ikegami; Tomomi Fujisawa; Maki Shintani; Yumiko Kawabata; Koji Nojima; Masaya Ono; Masanori Nisino; Michiko Itoi-Babaya; Naru Babaya; Toshio Ogihara

Background:  The purpose of the present paper was to study the effect of a new sulfonylurea, glimepiride, which has an extra‐pancreatic action that improves insulin resistance, on glycemic control and body weight gain in elderly patients with type 2 diabetes mellitus (DM).


BMC Genetics | 2014

Genetic dissection of susceptibility genes for diabetes and related phenotypes on mouse chromosome 14 by means of congenic strains

Naru Babaya; Hironori Ueda; Shinsuke Noso; Yoshihisa Hiromine; Michiko Itoi-Babaya; Misato Kobayashi; Tomomi Fujisawa; Hiroshi Ikegami

BackgroundA susceptibility locus, Nidd2n, for type 2 diabetes has been mapped to mouse chromosome 14 (Chr 14) and confirmed using the consomic strain (C3H-Chr 14NSY) of the Nagoya-Shibata-Yasuda (NSY) mouse, an animal model of spontaneous type 2 diabetes. The aim of this study was to localize and characterize Nidd2n.ResultsWe constructed two novel congenic strains homozygous for different segments of NSY-Chr 14 on the control C3H/HeNcrj (C3H) background: R1 (C3H.NSY-(D14Mit206-D14Mit5)) possesses the proximal and middle segment, and R2 (C3H.NSY-(D14Mit206-D14Mit186)) possesses the most proximal segment of NSY-Chr 14. Diabetes-related phenotypes were studied in comparison with those of consomic C3H-Chr 14NSY (R0) and parental NSY and C3H strains. Congenic R1 and R2 showed significantly higher post-challenge glucose than that in C3H mice. Fasting glucose, in contrast, was significantly lower in R1 and R2 than in C3H mice. Insulin sensitivity was significantly impaired in R1 and R2 compared to C3H mice. R2 showed significantly higher body weight and fat-pad weight than those in C3H and R1. Leptin level was significantly higher in R0, R1 and R2 than in C3H mice, with R2 showing the highest level, similar to that in NSY mice. Serum adiponectin level was significantly lower in R0, R1 and R2 than in C3H mice, while it was significantly higher in NSY than in C3H mice.ConclusionsThese data indicate that Chr 14 harbors multiple genes for diabetes-related phenotypes. The original Nidd2n, which is located in the middle region of Chr 14, was divided into two segments; Nidd2.1n in proximal Chr 14 and Nidd2.2n in distal Chr 14. Nidd2.1n contributes to post-challenge hyperglycemia, insulin resistance and adiposity. Nidd2.2n contributes to fasting as well as post-challenge hyperglycemia and insulin resistance. Adp1n, which contributes to decreased adiposity and increased insulin sensitivity, rather than a diabetogenic gene, was mapped in the middle segment.


Annals of the New York Academy of Sciences | 2006

Contribution of class III MHC to susceptibility to type 1 diabetes in the NOD mouse

Kaori Yamaji; Hiroshi Ikegami; Tomomi Fujisawa; Shinsuke Noso; Koji Nojima; Naru Babaya; Michiko Itoi-Babaya; Misato Kobayashi; Yoshihisa Hiromine; Susumu Makino; Toshio Ogihara

Abstract:  A recombinant major histocompatibility complex (MHC) with the same class III region as the NOD mouse, but different class II region from the NOD mouse was identified in the NON mouse, and NOD mice congenic for this recombinant MHC, NOD.NON‐H2, was established. None of the congenic mice homozygous for the NON MHC developed type 1 diabetes, indicating that the NOD MHC is necessary for the development of type 1 diabetes. A small portion of MHC heterozygotes developed late‐onset type 1 diabetes, suggesting the contribution of class III MHC to type 1 diabetes susceptibility.


Experimental Diabetes Research | 2013

Dose Effect and Mode of Inheritance of Diabetogenic Gene on Mouse Chromosome 11

Naru Babaya; Hironori Ueda; Shinsuke Noso; Yoshihisa Hiromine; Koji Nojima; Michiko Itoi-Babaya; Misato Kobayashi; Tomomi Fujisawa; Hiroshi Ikegami

The quantitative trait locus (QTL) mapping in segregating crosses of NSY (Nagoya-Shibata-Yasuda) mice, an animal model of type 2 diabetes, with nondiabetic strain C3H/He mice has identified diabetogenic QTLs on multiple chromosomes. The QTL on chromosome 11 (Chr11) (Nidd1n) showing the largest effect on hyperglycemia was confirmed by our previous studies with homozygous consomic mice, C3H-11NSY, in which the NSY-derived whole Chr11 was introgressed onto control C3H background genes. C3H-11NSY mice also showed a streptozotocin (STZ) sensitivity. In the present study, we constructed heterozygous C3H-11NSY mice and the phenotypes were analyzed in detail in comparison with those of homozygous C3H-11NSY and C3H mice. Heterozygous C3H-11NSY mice had significantly higher blood glucose levels and STZ sensitivity than those in C3H mice. Hyperglycemia and STZ sensitivity in heterozygous C3H-11NSY mice, however, were not as severe as in homozygous C3H-11NSY mice. The body weight and fat pad weight in heterozygous C3H-11NSY mice were similar to those in C3H and homozygous C3H-11NSY mice. These data indicated that the introgression of Chr11 of the diabetes-susceptible NSY strain onto diabetes-resistant C3H caused marked changes in the glucose tolerance and STZ susceptibility even in a heterozygous state, and suggested that the mode of inheritance of a gene or genes on Chr11 for hyperglycemia and STZ sensitivity is additive.


Metabolism-clinical and Experimental | 2005

Improvement of liver function parameters in patients with type 2 diabetes treated with thiazolidinediones

Masaya Ono; Hiroshi Ikegami; Tomomi Fujisawa; Koji Nojima; Yumiko Kawabata; Masanori Nishino; Hidenori Taniguchi; Michiko Itoi-Babaya; Naru Babaya; Kaori Inoue; Toshio Ogihara

Collaboration


Dive into the Michiko Itoi-Babaya's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge